Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-06-14 00:00:00 ET · period of report 2022-06-10 · accession 0000886163-22-000091 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-14 | 2022-06-10 | LGND | HIGGINS JOHN L | CEO, Dir | A - Grant | $0.00 | +20.4K | 369.0K | +6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-10 | A | A | 20,423 | $0.00 | 369,016 | D | — | — |